LOGIN
Romosozumab versus placebo, alendronate, and teriparatide for postmenopausal osteoporosis
February 2019
Romosozumab versus placebo, alendronate, and teriparatide for postmenopausal osteoporosis
Study Type:Meta analysis
OE Level Evidence:2
Journal Level of Evidence:N/A
Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials
Climacteric. 2018 Apr;21(2):189-195Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Six randomized controlled trials were included in this meta-analysis which compared the effects of romosozumab to placebo, teriparatide, and alendronate in postmenopausal osteoporosis treatment. The change in bone mineral density at the lumbar spine, total hip, and femoral neck significantly favoured romosozumab versus both placebo and active controls. Fracture rates after 24 months also significa...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.